Disease Detail

ID DOID:3234
Name central nervous system lymphoma
Definition A hematologic cancer that has_material_basis_in lymphoma located_in central nervous system.
Source DiseaseOntology.org
Alt Ids DOID:3233
Path disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer central nervous system lymphoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Rituximab central nervous system lymphoma not applicable detail...
Unknown unknown Ibrutinib central nervous system lymphoma not applicable detail...
MYD88 L265P Ibrutinib central nervous system lymphoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00267865 Phase II Rituximab Methotrexate Leucovorin Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma Recruiting
NCT00293475 Phase Ib/II Filgrastim Pegfilgrastim Leucovorin Carboplatin + Methotrexate + Rituximab Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL Recruiting
NCT00621036 Phase II Methotrexate Thiotepa Sargramostim Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Withdrawn
NCT02203526 Phase I Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal-doxorubicin + Temozolomide Cytarabine Rituximab Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma Recruiting
NCT02301364 Phase II Buparlisib Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed
NCT02315326 Phase Ib/II Ibrutinib Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) Recruiting
NCT02669511 Phase II PQR309 PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Completed
NCT02857426 Phase II Nivolumab A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647) Recruiting
NCT03220646 Phase II Abemaciclib The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors. Recruiting
NCT03558750 Phase Ib/II Lenalidomide + Nivolumab + Rituximab Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma Terminated
NCT03581942 Phase Ib/II Copanlisib + Ibrutinib Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) Recruiting
NCT03703167 Phase I Ibrutinib + Lenalidomide + Rituximab Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) Recruiting
NCT03770416 Phase II Ibrutinib + Nivolumab Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma Recruiting